These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36993137)

  • 21. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis.
    Uthman OA; Okwundu C; Gbenga K; Volmink J; Dowdy D; Zumla A; Nachega JB
    Ann Intern Med; 2015 Jul; 163(1):32-9. PubMed ID: 26148280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
    Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Influencing factors of antiretroviral therapy and its association with immunological effect among HIV/AIDS patients in Taizhou city, 2006-2019].
    He JY; Wang SL; Xu YY; Shen WW; Ding YY; Lin HJ; He N; Chen XX
    Zhonghua Liu Xing Bing Xue Za Zhi; 2020 Dec; 41(12):2093-2097. PubMed ID: 33378822
    [No Abstract]   [Full Text] [Related]  

  • 24. HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group.
    Phillips AN; Eron JJ; Bartlett JA; Rubin M; Johnson J; Price S; Self P; Hill AM
    AIDS; 1996 Jul; 10(8):859-65. PubMed ID: 8828743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052.
    Palumbo PJ; Fogel JM; Hudelson SE; Wilson EA; Hart S; Hovind L; Piwowar-Manning E; Wallis C; Papathanasopoulos MA; Morgado MG; Saravanan S; Tripathy S; Eron JJ; Gallant JE; McCauley M; Gamble T; Hosseinipour MC; Kumarasamy N; Hakim JG; Pilotto JH; Kumwenda J; Akelo V; Godbole SV; Santos BR; Grinsztejn B; Panchia R; Chariyalertsak S; Makhema J; Badal-Faesen S; Chen YQ; Cohen MS; Eshleman SH
    J Acquir Immune Defic Syndr; 2018 Apr; 77(5):484-491. PubMed ID: 29293156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A clinical algorithm for same-day HIV treatment initiation in settings with high TB symptom prevalence in South Africa: The SLATE II individually randomized clinical trial.
    Maskew M; Brennan AT; Fox MP; Vezi L; Venter WDF; Ehrenkranz P; Rosen S
    PLoS Med; 2020 Aug; 17(8):e1003226. PubMed ID: 32853271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines.
    Cid-Silva P; Margusino-Framiñán L; Balboa-Barreiro V; Pernas-Souto B; Mena-De-Cea Á; Martín-Herranz I; Castro-Iglesias Á; Poveda E
    J Int Assoc Provid AIDS Care; 2019; 18():2325958218821940. PubMed ID: 30798655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
    Havlir DV; Kendall MA; Ive P; Kumwenda J; Swindells S; Qasba SS; Luetkemeyer AF; Hogg E; Rooney JF; Wu X; Hosseinipour MC; Lalloo U; Veloso VG; Some FF; Kumarasamy N; Padayatchi N; Santos BR; Reid S; Hakim J; Mohapi L; Mugyenyi P; Sanchez J; Lama JR; Pape JW; Sanchez A; Asmelash A; Moko E; Sawe F; Andersen J; Sanne I;
    N Engl J Med; 2011 Oct; 365(16):1482-91. PubMed ID: 22010914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of antiretroviral therapy initiation time and baseline CD4
    Yang Y; Li Y; Zhang X; Zhang W; Ma Y; Jia X; Gondwe T; Wang Y; Shi X
    Glob Health Action; 2021 Jan; 14(1):1963527. PubMed ID: 34592916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical, Immunological and Virological Responses of Zidovudine-Lamivudine-Nevirapine
    Sorsa A
    Open Med Inform J; 2018; 12():11-18. PubMed ID: 29875890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old.
    Siegfried N; Davies MA; Penazzato M; Muhe LM; Egger M
    Cochrane Database Syst Rev; 2013 Oct; 10(10):CD010309. PubMed ID: 24114324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis.
    Eshun-Wilson I; Okwen MP; Richardson M; Bicanic T
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD009012. PubMed ID: 30039850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.
    Cotton MF; Violari A; Otwombe K; Panchia R; Dobbels E; Rabie H; Josipovic D; Liberty A; Lazarus E; Innes S; van Rensburg AJ; Pelser W; Truter H; Madhi SA; Handelsman E; Jean-Philippe P; McIntyre JA; Gibb DM; Babiker AG;
    Lancet; 2013 Nov; 382(9904):1555-63. PubMed ID: 24209829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults.
    Li J; Chen D; Wen Z; Du Y; Huang Z; Zhong H; Wang Y; Yin S
    Medicine (Baltimore); 2022 Oct; 101(42):e31100. PubMed ID: 36281149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Timing of antiretroviral therapy for HIV-infected patients with moderate to severe Pneumocystis pneumonia: study protocol for a multi-centre prospective randomised controlled trial.
    Qin Y; Lu Y; Zhou Y; Harypursat V; Sun F; Yang S; Tang S; Li Y; He X; Zeng Y; Chen Y
    Trials; 2020 Jun; 21(1):551. PubMed ID: 32571429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Could a Dolutegravir-Based Antiretroviral Therapy Lead to Clinical Obesity? A Retrospective Cohort Study Conducted at Hawassa University Comprehensive Specialized Hospital in Hawassa, Sidama, Ethiopia.
    Eifa BA; Ketema W
    AIDS Res Treat; 2022; 2022():2965325. PubMed ID: 35603131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of incident tuberculosis on immunological response of HIV patients on highly active anti-retroviral therapy at the university of Gondar hospital, northwest Ethiopia: a retrospective follow-up study.
    Assefa A; Gelaw B; Getnet G; Yitayew G
    BMC Infect Dis; 2014 Aug; 14():468. PubMed ID: 25164855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes of patients infected with HIV through use of injected drugs compared to patients infected through sexual transmission: late presentation, delayed anti-retroviral treatment and higher mortality.
    Suárez-García I; Sobrino-Vegas P; Dalmau D; Rubio R; Iribarren JA; Blanco JR; Gutierrez F; Montero Alonso M; Bernal E; Vinuesa García D; Del Amo J;
    Addiction; 2016 Jul; 111(7):1235-45. PubMed ID: 26890155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
    Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
    J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.